Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 29,395,242
  • Shares Outstanding, K 249,070
  • Annual Sales, $ 1,702 M
  • Annual Income, $ -112,050 K
  • 36-Month Beta 0.72
  • Price/Sales 17.26
  • Price/Cash Flow 839.46
  • Price/Book 17.45

Price Performance

See More
Period Period Low Period High Performance
1-Month
113.66 +4.65%
on 05/05/17
121.96 -2.48%
on 05/02/17
+2.24 (+1.92%)
since 04/21/17
3-Month
84.39 +40.94%
on 02/23/17
121.96 -2.48%
on 05/02/17
+33.15 (+38.64%)
since 02/22/17
52-Week
71.46 +66.44%
on 12/22/16
121.96 -2.48%
on 05/02/17
+34.24 (+40.43%)
since 05/20/16

Most Recent Stories

More News
Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their Immediate Family Members

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program. Each of the 40 scholarship recipients will...

VRTX : 118.94 (+0.78%)
SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 1.70% Gain

Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $115.42 to a high of $118.61. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day...

VRTX : 118.94 (+0.78%)
SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 1.70% Gain

Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $115.42 to a high of $118.61. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day...

VRTX : 118.94 (+0.78%)
Concert Pharma Falls After Clinical Hold on Hair Loss Drug

Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543...

CNCE : 14.04 (-2.97%)
VVUS : 1.08 (+3.85%)
VRTX : 118.94 (+0.78%)
INCY : 134.43 (+2.28%)
Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion

Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.

AGLE : 6.20 (-4.32%)
VVUS : 1.08 (+3.85%)
VRTX : 118.94 (+0.78%)
MEIP : 1.64 (+1.23%)
Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment

Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment

ETSY : 13.15 (-1.20%)
VRTX : 118.94 (+0.78%)
LYV : 33.92 (+0.18%)
PTC : 55.93 (+1.69%)
CVA : 14.55 (+2.46%)
Vertex Pharmaceuticals' Shares Pop in Afterhours Trading After FDA Approval while AstraZeneca Sinks on Clovis Upgrade

NEW YORK, NY / ACCESSWIRE / May 18, 2017 / Vertex Pharmaceuticals may have closed in the red yesterday but the stock saw a jump in share price in after-hours trading after the company reported exciting...

AZN : 33.95 (+0.15%)
VRTX : 118.94 (+0.78%)
FDA Approves KALYDECO(R) (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations

--- Vertex working with FDA to obtain rapid approval for more than 600 additional people who have mutations responsive to KALYDECO, including one of five "splice" mutations -

VRTX : 118.94 (+0.78%)
Vertex Pharmaceuticals Shares Up 47.8% Since SmarTrend's Buy Recommendation (VRTX)

SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on January 6th, 2017 at $78.63. In approximately 4 months, Vertex Pharmaceuticals has returned 47.81% as of today's recent price...

VRTX : 118.94 (+0.78%)
5 Toxic Stocks to Steer Clear Of or Play Short Right Now

High price of the toxic stocks can be ascribed to an irrational exuberance associated with them or some serious fundamental lacunae. Presence of such stocks in your portfolio may result loss of wealth....

ETSY : 13.15 (-1.20%)
LYV : 33.92 (+0.18%)
VRTX : 118.94 (+0.78%)
PTC : 55.93 (+1.69%)
CVA : 14.55 (+2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its...

See More

Support & Resistance

2nd Resistance Point 120.33
1st Resistance Point 119.64
Last Price 118.94
1st Support Level 117.88
2nd Support Level 116.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.